Deal takeaways - Strong platform validation for Shengyin’s RNAi chemistry and delivery technologies - Meaningful non-dilutive capital with retained upside via milestones and royalties - Genentech assumes late-stage development and commercialization risk, a classic risk-sharing structure - Signals continued Big Pharma appetite for RNAi assets, especially platform-driven programs From an investment perspective, this deal highlights how differentiated RNA platforms can command premium economics even at early clinical stages—and how large pharma is selectively re-entering RNAi with improved delivery solutions.

RNAi deal worth watching from an investment lens
SanegeneBio announced a global licensing agreement with Genentech (罗氏公司 Group) for an RNAi therapeutic, featuring $200M upfront, up to $1.5B in milestones, plus tiered royalties.
#BiotechInvesting #RNAi #LicensingDeals #PharmaBD #Roche #Genentech

Master patient-based, pricing & scenario-driven pharma forecasting with hands-on models. Think strategically. Forecast confidently.

🔗 zurl.co/COaAk

#PharmaForecasting #PharmaStrategy #PharmaBD #MarketAccess #RoyedTraining

Discover how to crack international markets with the right regulatory, licensing & sales strategy.

📘 Read: How to Sell APIs to International Clients
👉 zurl.co/LiA9q

#API #PharmaExports #PharmaBD #RoyedTraining #PharmaStrategy

middle east business development royed training

🧭 Navigate and Thrive in the Middle East Pharma Landscape!

📘 Executive Certification in Middle East Pharma BD by #RoyedTraining
✅ BD Strategies | ✅ Market Access | ✅ Licensing Insights

🔗 zurl.co/4B1g7
#PharmaBD #MiddleEastPharma 🌍💼

global api business

🌍 Master the Global API Business!
Enroll in Royed’s 360° Executive Program in API Business Development 💊📈
✅ Licensing | Sourcing | BD Strategy | Regulatory
🔗 zurl.co/TbnA4
#API #PharmaBD #RoyedTraining #PharmaIndustry #CDMO #TechTransfer #PharmaBusiness